First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.
Saved in:
| Title: | First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. |
|---|---|
| Authors: | Kim SB; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. sbkim3@amc.seoul.kr., Meric-Bernstam F; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kalyan A; Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Babich A; Bayer AG, Berlin, Germany., Liu R; Bayer Healthcare, Whippany, NJ, USA., Tanigawa T; Bayer Yakuhin, Ltd., Osaka, Japan., Sommer A; Bayer AG, Berlin, Germany., Osada M; Bayer AG, Berlin, Germany., Reetz F; Bayer AG, Basel, Switzerland., Laurent D; Bayer AG, Berlin, Germany., Wittemer-Rump S; Bayer AG, Berlin, Germany., Berlin J; Vanderbilt University Medical Center, Nashville, TN, USA. |
| Source: | Targeted oncology [Target Oncol] 2019 Oct; Vol. 14 (5), pp. 591-601. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1776-260X |
|---|---|
| DOI: | 10.1007/s11523-019-00670-4 |
